Plasticity and Tumorigenicity by Campos-Sánchez, Elena et al.
   
 
 
 
 
 
Deep Insight Section 
 
Atlas Genet Cytogenet Oncol Haematol. 2012; 16(3)  238 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
Plasticity and Tumorigenicity 
Elena Campos-Sanchez, Isidro Sanchez-Garcia, Cesar Cobaleda 
Centro de Biologia Molecular "Severo Ochoa", CSIC/Universidad Autonoma de Madrid, C/Nicolas Cabrera 
1, Universidad Autonoma, Cantoblanco, 28049 Madrid, Spain (ECS, CC), Experimental Therapeutics and 
Translational Oncology Program, Instituto de Biologia Molecular y Celular del Cancer, CSIC/ Universidad 
de Salamanca, Campus M de Unamuno s/n, 37007-Salamanca, Spain (ISG) 
 
Published in Atlas Database: September 2011 
Online updated version : http://AtlasGeneticsOncology.org/Deep/PluripotencyID20103.html 
DOI: 10.4267/2042/47289 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Summary 
The research fields of developmental biology and oncology have always been tightly linked, since the times of Rudolf 
Virchow's cellular theory ("omnis cellula e cellula") and embryonal rest hypothesis. On the other side, for many years, 
contemporary cancer research has been mainly focused on the altered controls of proliferation in tumoral cells. This has 
been reflected in the therapeutic approaches employed in the clinic to treat the patients: with very few exceptions, anti-
cancer treatments are targeted at the mechanisms of abnormal tumoral growth. Such therapies, however, are very 
unspecific, highly toxic and, ultimately, inefficient in most cases. In the last years, a new recognition of the role of 
aberrant differentiation at the root of cancer has arisen, mainly driven by the coming of age of the "cancer stem cell" 
(CSC) theory. From this point of view, the comprehensive knowledge of the developmental mechanisms by which 
normal cells acquire their identity is essential to understand how these controls are deregulated in tumours. New insights 
into the mechanisms that maintain the molecular boundaries of cell identity have been gained from the study of induced 
pluripotency, showing that cell fate can be much more susceptible to change than previously thought. Applied to cancer, 
these findings imply that the oncogenic events that take place in an otherwise healthy cell lead to a reprogramming of 
the normal cellular fate and establish a new pathologic developmental program. Therefore, cancer reprogramming and 
cellular plasticity are closely related, since only some cells possess the plasticity required to allow reprogramming to 
occur, and only some oncogenic events can, in the right plastic cell, induce this change. Here we discuss the latest 
findings in the fields of cellular plasticity and reprogramming and we consider their consequences for our understanding 
of cancer development and treatment. 
 
Historical perspective 
The search for the capacity of regenerating disease-
affected organs is probably as old as mankind 
(Odelberg, 2004). The examples are abundant in 
ancient religions, from the Egyptian god Osiris, who 
resurrected and recomposed his maimed body from the 
pieces that had been thrown into the Nile, to the 
legendary Hydra that could regenerate its severed 
heads. Or the mythological Prometheus, who had his 
viscera eaten by an eagle every day, only to regenerate 
them again. But also from a more scientific point of 
view, it was already noticed by Aristotle (384-322 BC) 
that lizards can regenerate their tails after amputation. 
But until the 18th century this knowledge was mainly 
anecdotic, and only with the arrival of the Age of 
Enlightenment, regeneration and plasticity will become 
the matter of scientific research. In 1712, Réaumur 
describes the regeneration of the limbs and claws of 
crayfish (Réaumur, 1712); in 1744, Trembley discovers 
that a part of the Hydra polyp can regenerate the 
complete organism (Trembley, 1744); in 1769, 
Spallanzani reports that tadpoles can regenerate their 
tails and salamanders their amputated jaws, limbs and 
tails (Spallanzani, 1769). The research performed 
during most of the 19th and first half of the 20th 
centuries showed that, for regeneration to occur, the 
cells that are normally forming part of the organs are 
not sufficient, and a special type of cells are required: 
the progenitor cells (Odelberg, 2004; Birnbaum and 
Sánchez Alvarado, 2008). The origin of these cells was 
not very clear (and it is still a matter of debate and 
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intense research, in fact, see (Sánchez Alvarado, 2000; 
Kragl et al., 2009; Rinkevich et al., 2011)); for some 
tissues, like skin, blood, muscles or bones, progenitors 
were shown to exist in the tissues in small numbers, 
and to become activated as a consequence of the 
lesions. In other cases, the progenitors seemed to arise 
from mature cells that become dedifferentiated. The 
best example supporting this possibility has been 
described in primitive vertebrates like the urodeles (e.g. 
salamanders and axolotls). In these animals, after a 
wound harms the organism, the cells from the normal 
tissues form a group of cells known as the regenerative 
blastema, which will generate all the tissues in the new 
limb/tail (Chalkey, 1954; Bodemer and Everett, 1959; 
Hay and Fischman, 1961). It has long been held that the 
blastema was the result of cellular dedifferentiation to 
progenitors. However, the most recent findings seem to 
indicate that there is no cellular dedifferentiation to 
progenitors involved in this process, and the 
regeneration is always due to the action of resident 
tissue-specific stem cells and progenitors, thus 
questioning the role of mature cellular plasticity in 
tissue regeneration (Kragl et al., 2009; Rinkevich et al., 
2011). We have therefore seen how the study of 
"naturally" occurring regeneration opened the way to a 
new understanding of the stem cell-based architecture 
of the organs and tissues, especially with the study of 
primitive vertebrates. In 1952, amphibians also 
provided the first animal model of experimentally-
induced reprogramming when Briggs and King 
generated Xenopus tadpoles by transplanting the 
nucleus of cells from the blastula into oocytes, 
therefore reverting the cellular differentiation program 
(Briggs and King, 1952). Afterwards, it was shown that 
more differentiated cells, like those from the intestinal 
epithelia, could also be reprogrammed by nuclear 
transfer (Gurdon, 1962). These landmark findings 
undoubtedly showed that the genetic potential of cells 
was not lost during differentiation, and that 
development did not imply genetic changes. This 
principle was extended to mammals with the cloning of 
Dolly the sheep in 1997 (Wilmut et al., 1997). This was 
the ultimate proof showing that the changes that occur 
during differentiation are totally reversible, and 
demonstrated that the fate restrictions that take place 
during development are the result of epigenetic 
modifications. These studies also showed that there 
were factors in the oocyte cytoplasm capable of 
inducing a reprogramming that led to the appearance of 
a totipotent phenotype. 
In a parallel way, the search for the molecular 
regulators responsible for establishing and controlling 
cellular identity led finally to the identification of the 
factors capable of reprogramming cellular fate. In 
1987, it was shown that ectopic expression of the 
Antennapedia homeotic gene lead to changes in the 
body plan of Drosophila, that got extra legs instead of 
antennae (Schneuwly et al., 1987). Also, Gehring et al. 
showed that the ectopic expression of eyeless 
controlled eye development and led to the development 
of ectopic eyes in the fly's legs (Gehring, 1996). In 
mammals, the first master regulator factor to be 
identified was MyoD, which was shown to be capable 
of transdifferentiating fibroblasts into the myogenic 
lineage (Davis et al., 1987). Other examples of factors 
with fate-reprogramming capacity are C/EBPα, capable 
of mediating the transdifferentiation of mouse B cells 
into macrophages (Xie et al., 2004) or Pax5, whose loss 
leads to the dedifferentiation of committed B cells 
(Nutt et al., 1999; Cobaleda et al., 2007a; Cobaleda and 
Busslinger, 2008). All these data proved that the lack or 
excess of just one factor could lead to a radical 
alteration of the transcriptional profile and could cause 
stable fate changes. This evidence, together with the 
one coming from reprogramming by nuclear 
transplantation, paved the way to the search for the 
factors capable of reprogramming to full pluripotency 
that led, in 2006, to the identification of the four 
transcription factors capable of inducing pluripotency 
in virtually every kind of terminally differentiated cells 
(Takahashi and Yamanaka, 2006). We will discuss this 
aspect with more detail afterwards. 
On the other side, cancer has also been recognized as a 
distinct pathological entity since the origins of 
mankind. The first references are the Edwin Smith and 
Ebers papyri from the 1600 BC and 1500 BC, 
approximately (Hajdu, 2004). The Edwin Smith 
papyrus contains the first mention and description of 
breast cancer, and it concludes that there is no 
treatment for the disease. Cancer was not so common in 
ancient times, mainly because life span was much 
shorter, but it was already clearly recognized. 
Hippocrates (460-375 BC) realized that growing 
tumors occurred typically in adults and they reminded 
him of a moving crab, which led to the terms carcinos 
and cancer. Celsus (25 BC-AD 50) also compared 
cancer with a crab, because it penetrates the 
surrounding organs like if it had claws; Celsus 
introduced the first classification for breast cancer and 
advocated for surgical therapy. Furthermore, he already 
realized that tumors could only be cured if they were 
removed in their early stages and that, even after 
removal and wound healing, breast carcinomas tended 
to recur causing swelling in the armpit and, finally, 
death by spreading throughout the body. Galen (131-
AD 200) already recommended surgery by cutting a 
wide margin of healthy tissue around the edges of the 
tumor (Hajdu, 2004). If we jump now to our days, it 
seems disappointing to see how little those old critical 
findings have been overcome by modern medicine, 
2000 years later. Indeed, still today, clean surgical 
margins and lack of lymph node invasion are the most 
important prognostic markers for the successful 
eradication of solid tumors, and only if tumors are 
completely resected before they metastasize (something 
that it is anyhow impossible to determine with current 
technologies) can curation be guaranteed. However, in 
the last thirty years we have gained an enormous 
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knowledge about the molecular biology of the disease. 
In 1979, it was shown that the phenotype of 
transformed cells could be transferred to normal 
fibroblasts by DNA transfection (Shih et al., 1979), a 
finding that lead to the rapid molecular cloning of the 
first human oncogene (the RAS gene), simultaneously 
by several groups (Goldfarb et al., 1982; Lane et al., 
1982; Parada et al., 1982; Santos et al., 1982). Since 
then, many genes have been described as being either 
oncogenes or tumor suppressors, and the molecular 
mechanisms of their transforming capabilities have 
been analyzed to great detail, in close relationship with 
their functions in "normal" conditions. This is a field 
that has expanded tremendously in the last decades, and 
a comprehensive study of the topic falls out of the 
scope of this revision. However, there are some aspects 
that must be taken into account for posterior debate. A 
very important one is the fact that, for many types of 
tumors, specific genetic mutations have been shown to 
correlate closely with the phenotype of the tumors, 
suggesting that the oncogenic alterations might be 
acting as new specification factors that determine the 
tumor appearance and/or phenotype. This association is 
especially evident in the case of mesenchymal tumors 
caused by chromosomal aberrations (Sánchez-García, 
1997; Cobaleda et al., 1998). In 2000, Hanahan and 
Weinberg summarized the main features that had to be 
disrupted in normal cellular behavior in order for allow 
a tumor to appear and progress (Hanahan and 
Weinberg, 2000), and this list has expanded with the 
years (Hanahan and Weinberg, 2011). These main 
aspects are related with the survival and proliferation of 
cancer cells, but it must be noted that most of them are 
equally shared by non-malignant tumors (Lazebnik, 
2010). However, all the aspects related to the 
alterations of the normal developmental regulatory 
mechanisms in tumorigenesis have received much less 
attention. But in fact, if cellular fate was carved into 
stone, cancer would be impossible, since no new 
lineages could be generated other than the normal, 
physiologic ones. Here is where the normal  
 
mechanisms regulating cellular identity and plasticity 
play an essential role in allowing cancers to arise and 
hopefully, as we will discuss, they might be the key to 
its eradication. 
The specification of cellular identity during 
development and differentiation is a dynamic process 
that starts with stem and progenitor cells and ends with 
terminal differentiation into each specialized cellular 
type. In this progression there can be many cellular 
intermediates; some of them are transient, and some 
can be long-lasting, but the maintenance of cellular 
identity at each stage is determined by the signals from 
the environment and, in an intrinsic manner, by specific 
transcription factors and epigenetic modifiers that 
establish a defined chromatin architecture and a 
specific gene expression profile. 
As we have seen, evidences about cellular plasticity 
had being accumulating for decades (Hochedlinger and 
Jaenisch, 2006; Gurdon and Melton, 2008; Graf and 
Enver, 2009; Vicente-Dueñas et al., 2009a), but the 
latest findings in the field of reprogramming have 
definitively shown how switching to a different 
phenotype can be a lot easier than previously expected, 
and can have real physiological relevance, beyond 
basic research. Cancer is a perfect example of 
pathological reprogramming in which, from a normal 
tissue, a whole new differentiation lineage is opened 
with its own hierarchy and structure (Reya et al., 2001; 
Sánchez-García et al., 2007). So, without forgetting the 
so well-studied aberrant proliferation, reprogramming 
is an essential part of the tumorigenesis process, and it 
is closely dependent on the cellular plasticity of the 
cancer-initiating cells. The term plasticity, as we will 
use it here, refers to the ability of cells (stem or 
differentiated) to adopt the biological properties (gene 
expression profile, phenotype, etc.) of other 
differentiated types of cells (belonging to the same or 
different lineages). This definition comprises also the 
property of competence, i.e. the ability of stem cells 
and progenitors to give rise to their different 
descendant lineages during normal development. We 
use such an ample definition of the term precisely to 
reflect the fact that the molecular mechanisms that are 
important for progenitors' competence during normal 
development are the same ones responsible for the 
plasticity changes of more differentiated types of cells, 
both in pathological processes and in experimentally-
induced reprogramming. Here we will discuss the vital 
role of cellular plasticity in the origin and maintenance 
of tumoral cells. We will first revise the latest research 
discoveries in the fields of normal developmental and 
experimentally-induced plasticity, and afterwards will 
link these findings with what we know about cancer 
biology. 
Lineage commitment and cellular 
identity 
Adult stem cells are the responsible of generating all 
the different specialized cellular types forming the 
organism. The majority of them perform this job 
throughout the whole life of the organism, thanks to 
their self-renewal capacity. This property allows them 
to divide asymmetrically, therefore given rise to a new 
identical daughter stem cell and to a multipotential 
progenitor, lacking self-renewal capacity, which will 
give rise to all the differentiated tissue cells. Although 
it is known that there are some specific factors that are 
essential for the specification and maintenance of stem 
cell identity (Boyer et al., 2005), the molecular bases of 
the choice that stem cells have to make between 
maintaining competence (i.e. plasticity) or entering into 
the differentiation programs are not yet completely 
understood (Niakan et al., 2010). In this context, a first 
important aspect to consider is the fact that the stem  
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cell population itself is intrinsically heterogeneous. 
This means that the "stemness" is not a static condition 
defined by stable, constant levels of expression of 
intrinsic stem factors and surface stem markers, but it is 
more of a continuum that moves within certain 
margins. For example, in a clonal population of 
haematopoietic progenitor cells, there is a Gaussian 
distribution of the levels of expression of Sca-1, one of 
the most classical stem cell markers (Chang et al., 
2008). Furthermore, cells at both the low- or high-end 
levels of expression can, when isolated, regenerate the 
whole population with all the range of expression 
levels. However, every one of these sub-populations, 
defined by their levels of a surface marker, also 
expresses different transcriptomes, and has therefore 
distinct intrinsic differentiation tendencies towards 
different lineages. Therefore, each individual cell in the 
stem population represents a metastable transitional 
point in a continuum of constantly changing 
transcriptomes. In fact, this is most probably the 
mechanism at the basis of the stochastic choice of 
lineage, when some cells approach too much to the 
"edges" of the normal distribution and the 
transcriptome changes become irreversible (Chang et 
al., 2008). 
In 1957 Waddington conceptualized the irreversible 
process of cellular differentiation as marbles falling 
down a slope (Waddington, 1957). This metaphorical 
concept has regained new momentum with the 
mathematical interpretation of transcriptional cellular 
states as Gene Regulatory Networks (GRNs). In this 
type of analysis, pluripotency is represented as a 
mathematical attractor (a condition towards which a 
dynamical system tends to progress over time), in such 
a way that the points (cells) that get close enough to the 
attractor remain close even if slightly disturbed. This 
attractor is surrounded by a "differentiation landscape" 
where other stable cellular fates are represented by 
stable "valleys" and differentiation routes towards them 
are "channels" through which the cells move (Enver et 
al., 2009; Huang, 2009). Under this light, pluripotency 
can be considered as a dynamic state of controlled 
heterogeneity within a population, where small 
individual fluctuations in the levels of expression of 
transcription factors and epigenetic regulators maintain 
a global status of apparent stability. The cells that 
approach the limits of the attractor (those who, in their 
random fluctuations, go too far from the middle point 
of the Gaussian curve) are therefore more prone to 
differentiate, suggesting that commitment, although 
rare, is an spontaneous phenomenon (unless it is 
specifically triggered by an external signal that 
unbalances the dynamic equilibrium) (Huang, 2009). 
Maintenance of cellular identity 
throughout the differenciation 
process 
Although in some rare cases they are unipotent (e.g.  
spermatogonial stem cells), adult stem cells are usually 
multipotent, and they can give rise to a wide range of 
differentiated cell types. In the first instance, stem cells 
lose their self-renewal potential (their stemness) and 
start the differentiation process by becoming 
multipotential progenitors. We have seen that the 
differentiation program can be pre-set already by the 
oscillatory patterns of gene expression at the stem cell 
population level, and that cells lying at the different 
ends of specific gradients of gene expression can have 
opposite differentiation preferences (Chang et al., 
2008). So, once they leave the stem cell state, the cells 
start making lineage choices that are usually mutually 
excluding and are normally conceptualized in a 
branching pattern. These alternative options are usually 
controlled by the cross-antagonism between 
transcription factors with competing, opposing 
functions (Swiers et al., 2006; Loose et al., 2007). A 
very well characterized developmental system is 
hematopoietic differentiation where several models of 
lineage-specification have been identified which seem 
to be based on the aforementioned mechanism. For 
example, the choice between erythroid/megakaryocyte 
or myeloid-monocytic fates at the level of 
erythromyeloid progenitors is controlled by the 
reciprocal inhibition between the transcription factors 
GATA-1 and PU.1, therefore creating a binary decision 
for the progenitor (Laiosa et al., 2006; Enver et al., 
2009). The bipotent progenitor itself would therefore be 
this intermediate state created and maintained by the 
equilibrium between the both factors. This fact helps 
understanding the phenomenon of multilineage gene 
priming, in which uncommitted progenitors present low 
levels of simultaneous expression of multiple 
transcription factors corresponding to different mature 
cell types and possessing antagonistic functions (Hu et 
al., 1997; Enver et al., 2009). In general, there seems to 
be a progressive loss of developmental potential in a 
hierarchical process that moves through sequential 
differentiation options and in which, at any given point, 
a progenitor would only have to choose between two 
mutually exclusive options (Brown et al., 2007; 
Ceredig et al., 2009). Additionally, in the process of 
maturation into a given lineage, the progenitors will 
receive (and react to) the necessary extrinsic signals 
(for example, cytokines) that, according to this model, 
would be more permissive than instructive. 
Maintenance of the cellular identity 
of mature differentiated cells 
Plasticity, in normal development, is a property that is 
"intended" to be restricted to stem cells and 
progenitors. In general, the final differentiated cellular 
types of any given organ or tissue possesses stable 
identities, in consequence with the fact that they 
usually are highly specialized cells with very specific 
physiological functions. Therefore, it would not make 
sense, from the biological point of view, that a  
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specialized cell would be the source of other 
differentiated cell types. This, as we have mentioned, is 
the role of stem cells, with their physiological plasticity 
(i.e., normal competence) that we have previously 
discussed. However, the concept of the stability of 
differentiated cell types has been shaken by the 
discovery of the fact that the 4 Yamanaka transcription 
factors (4Y TFs) Oct4, Sox2, c-Myc and Klf4 
(Takahashi and Yamanaka, 2006) are enough for the 
reprogramming of most differentiated cells types into 
induced pluripotent stem cells (iPSCs). This finding has 
altered our notion of the latent developmental potential 
hidden in differentiated cells, showing how it can be 
"awakened" by experimental manipulations in the 
laboratory. This, as we have described, was already 
known to a certain extent from the nuclear 
reprogramming experiments performed in amphibians 
more than 50 years ago (Briggs and King, 1952; 
Gurdon, 1962). Nevertheless, although those 
experiments already proved that the cell nucleus could 
be reprogrammed from a differentiated cell type into a 
pluripotent progenitor, Yamanaka's experiments 
showed that only 4 factors were actually enough to 
make the whole process possible. We have seen that, a 
more modest level, it had already been proven that the 
overexpression or loss of individual transcription 
factors could induce fate changes in differentiated cells 
(MyoD, C/EBPa, Pax5, etc). Although these were 
examples of transdifferentiation taking place between 
closely related cell types, they already pointed the way 
for the search of the factors capable of reprogramming 
to full pluripotency. Since the differentiated state is the 
more stable one (indicating that the GRNs are less 
subject to fluctuation), where the cells have reached 
after "rolling down" the differentiation pathway in the 
normal process of development, therefore an 
"activation energy" is required to move the cells 
"uphill" to become again pluripotent. Conceptually, 
there are at least two main possible scenarios to explain 
the population dynamics in the process of 
reprogramming to pluripotency (Yamanaka, 2009): one 
possibility (the so-called elite model) is that only some 
cells can be reprogrammed, and these are the ones that 
are selected among the entire population, since they are 
the only ones that are receptive to the action of the 
reprogramming factors. Alternatively, it might happen 
that all the differentiated cells are equally capable of 
undergoing reprogramming, and it is only due to 
technical or methodological reasons that we are not 
able to reveal this potential in all of them (stochastic 
model). According to the accumulating evidences, it 
would seem that the stochastic model is the one that is 
closer to reality and that, given the right combination of 
factors; any cell could be reprogrammed to 
pluripotency (Yamanaka, 2009). However, as we have 
mentioned, this is a developmentally and energetically 
unfavourable process, a fact that is evidenced by 
several details. The most obvious one is the very low 
efficiency of the reprogramming process, even in the 
most favourable conditions. This fact clearly indicates 
that, independently on how many cells of the 
population are initially responsive to the 
reprogramming factors, very few of them can complete 
the path towards full reprogramming (Yamanaka, 
2009). Also, this is a gradual process in which several 
non-physiological cellular intermediates can be isolated 
(Mikkelsen et al., 2008; Stadtfeld et al., 2008). The 
study of these incompletely reprogrammed 
intermediates has revealed that they have re-activated 
the self-renewal and maintenance stem cell genes, but 
not yet those of pluripotency; also, these stages of 
aborted reprogramming have not been able to 
completely repress the expression of lineage-specific 
transcription factors and retain persistent DNA 
hypermethylation marks as a proof of their failure in 
achieving complete epigenetic remodelling (Mikkelsen 
et al., 2008). But perhaps the most patent proof of the 
difficulty of the process of full reprogramming to 
pluripotency is the persistence of an epigenetic memory 
in the iPCs that makes them more prone to re-
differentiate into the lineages from which they were 
initially derived, indicating that a complete elimination 
of the initial epigenetic program cannot yet be achieved 
(Kim et al., 2010; Bar-Nur et al., 2011). 
Tumoral reprogramming and 
induction of pluripotency: 
similarities 
The role of transcription factors in the control of 
tumoral reprogramming and induction of pluripotency 
We have seen in the initial section of this review that 
both cancer research and developmental biology have 
been the focus of intense attention since ancient times. 
What's more, they have always been closely related 
from the conceptual point of view. The cellular theory 
of Rudolf Virchow is clearly essential for the 
understanding of both development and 
tumorigenenesis. But he went further, since he already 
proposed the embryonal rest hypothesis of tumour 
origin, after realising the histological similarities 
between tumours and embryonic tissues (Virchow, 
1855). This concept was afterwards expanded by Julius 
Conheim, who suggested that tumours arise from 
residual embryonic remnants "lost" during normal 
development (Cohnheim, 1867). This hypothesis 
actually connects with the current theory of the cancer 
stem cells (CSCs) in which progenitors are situated at 
the root of cancer maintenance (see below). Another 
example of the influence of cancer research in the 
progress of the fields of stem cell biology and 
developmental biology is the fact that embryonic stem 
(ES) cells were identified in a search that has been 
initiated in the study of teratocarcinomas (Solter, 2006; 
Morange, 2007; Hochedlinger and Plath, 2009). 
In the field of cancer research it has traditionally been 
postulated that more than one molecular hit is required 
to generate a tumour cell, because several aspects of 
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cellular biology must be altered in the progress towards 
a full-blown tumour (Hanahan and Weinberg, 2000). 
Therefore, in order to achieve tumoral reprogramming 
(although this was not the terminology traditionally 
used), more than one single molecular alteration had to 
happen. We have mentioned before that for a "simple" 
transformation, like a lineage switch, the change in the 
levels of expression of a single transcription factor 
could be enough (Davis et al., 1987; Nutt et al., 1999; 
Xie et al., 2004; Cobaleda et al., 2007a). Similarly, a 
single initial oncogenic lesion may contribute to just a 
part of the tumoral phenotype, by causing a block in 
differentiation, or an alteration in the control of cell 
cycle. In oncogenesis, many factors and routes have 
been shown to be altered, and their individual 
contributions to the tumoral phenotype are clear, 
although their synergy and interactions are less known. 
In the case of reprogramming to pluripotency, the 
discovery of Takahashi and Yamanaka (Takahashi and 
Yamanaka, 2006) revealed the nature of these factors. 
Before, reprogramming to pluripotency was only 
possible by the use of nuclear transplantation, but it 
was not known which of the factors present in the 
zygote possessed the required reprogramming capacity. 
Interestingly enough, the 4 Yamanaka factors are 
known to be involved in tumorigenesis in different 
contexts, and both c-Myc and Klf4 are well-known 
oncogenes (Rowland et al., 2005; Okita et al., 2007; 
Tanaka et al., 2007; Chen et al., 2008), thus further 
linking reprogramming to tumorigenesis. 
In summary, the experimental results show that the 
maintenance of cellular identity is essential for 
differentiated cells, and that only strong transcriptional 
or epigenetic regulators can subvert it. In this way, the 
multistep nature of tumorigenesis is paralleled by 
reprogramming to pluripotency in the series of "uphill" 
steps required and in the need for the sum of the effects 
of several factors to overcome the built-in safety 
mechanisms designed to protect cells from 
transformation or, in other words, to prevent cells from 
changing their identity. In the case of the 
reprogramming factors, the precise role of each of them 
is not yet clear, but their experimental introduction at 
different times during the process of reprogramming is 
shedding some light on this issue (Sridharan et al., 
2009), by identifying distinct contributions of the 
different factors along the reprogramming progression. 
In the early stages of reprogramming, the most 
important process happening is the silencing of the 
gene expression programs of the differentiated cells. 
This aspect is previous to the induction of the ES-like 
expression program, and the main molecular 
responsible for this function seems to be c-Myc. 
However, it has also been shown that treatment with 
histone deacetylase inhibitors like valproic acid (VPA) 
can substitute for c-Myc, because of their capacity for 
repressing the gene expression programs of 
differentiated cells (Huangfu et al., 2008). Therefore, it 
would seem that the action of c-Myc takes place mainly 
before the activation of the regulators of the pluripotent 
state and, consequently, ectopic expression of c-Myc is 
required only during the first few days of the 
reprogramming process (Sridharan et al., 2009). In fact, 
c-Myc is dispensable for reprogramming, but in its 
absence there is an enormous drop in the efficiency of 
the procedure (Nakagawa et al., 2008; Wernig et al., 
2008). The other three factors, Oct4, Sox2, and Klf4, 
need to act together to achieve the entry into the 
pluripotent condition, as evidenced by the fact that, 
when they are used individually, they cannot bind their 
pluripotent target genes in cells that are sill 
incompletely reprogrammed, most likely because the 
pattern of epigenetic modifications at these loci is not 
permissive for their binding (Sridharan et al., 2009). 
Indeed, Oct4, Sox2, and also Nanog co-bind to a 
plethora of genes in overlapping genomic sites (Boyer 
et al., 2005; Loh et al., 2006), in such a way that the 
transcriptional program required for pluripotency is 
maintained by the coordinated action of these key 
genes. 
In general, for the reprogramming of almost every cell 
type to pluripotency, the 4 Yamanaka transcription 
factors are enough. However, there are some 
exceptional cases in which additional alterations are 
required. For example, in the case of mature B cells it 
is necessary to interfere with the activity of the 
transcription factor Pax5, which is the master regulator 
of B cell identity (Cobaleda et al., 2007a; Hanna et al., 
2008). Previous experiments had revealed that the 
elimination of Pax5, in the absence of any other genetic 
manipulation, allowed mature B cells to dedifferentiate 
to early haematopoietic multipotential progenitors 
(Cobaleda et al., 2007b). These findings again correlate 
reprogramming with cancer development, since it has 
also been shown that the elimination of Pax5 function 
in mature B cells induces a process of pathological 
dedifferentiation that gives rise to progenitor cell 
lymphomas (Cobaleda et al., 2007a). Therefore, the 
loss of a transcription factor that is required for the 
maintenance of cellular identity can be a tumour-
inducing lesion. However, and contrary to mature B 
cells, earlier stages of B cell development can be 
reprogrammed to pluripotency in the presence of 
functional Pax5, just with the 4 Yamanaka transcription 
factors (Hanna et al., 2008), thus supporting the 
intuitive idea that the degree of differentiation of the 
target cell has an effect on the final efficiency of 
reprogramming (see below). 
In the genetic landscape, the oncogenic mutations alter 
the architecture of the whole gene regulatory network, 
since it modifies one of the nodes. This leads to an 
alteration in the landscape that gives rise to new 
abnormal attractors (new "valleys") where cancer cells 
reside (Huang et al., 2009). Furthermore, this alteration 
in the landscape gives the cell a new momentum to 
move towards new directions, and this effect can 
persist even when the initial stimulus has disappeared. 
From the point of view of tumoral reprogramming, this 
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implies that the expression of a tumour-promoting 
gene, even if it is transient, can by itself trigger a 
durable malignant phenotype that does not require 
anymore of the initial mutation for its maintenance 
(Huang et al., 2009). 
The role of epigenetic factors in the control of tumoral 
reprogramming and induction of pluripotency 
In the previous section we have seen that either the gain 
or the loss of function of transcription factors plays an 
essential role in reprogramming to pluripotency, in the 
same way as how oncogene overexpression or loss of 
tumour suppressors promote tumorigenesis. Also, 
similarly to tumour progression, large-scale epigenetic 
changes are required for full reprogramming to happen. 
Today, it is clearly established that not only genetic 
alterations are responsible for cancer development, but 
there is also an important role of epigenetic alterations 
(Esteller and Herman, 2002; Esteller, 2007; Esteller, 
2008) that lead to the specification of an heritable, 
abnormal pattern of gene expression that plays an 
essential role in cancer initiation and progression (Ting 
et al., 2006). All the relevant epigenetic marks, from 
DNA methylation to histone modifications, are 
perturbed in tumour progression. The subsequent 
changes in gene expression patterns are especially 
relevant when they affect the levels of expression of 
specific oncogenes or tumour suppressors, but they 
affect in fact the whole epigenome, and therefore 
condition all cellular identity. All these epigenetic 
alterations are usually secondary, and they can be just 
due to tumour progression and therefore independent 
from (i.e., not directly caused by) the initiating 
oncogenic mutation, but they can also be directly 
induced by the first oncogenic event, like it happens 
when chromosomal aberrations deregulate histone 
modification genes (Esteller, 2008). In the process of 
reprogramming to pluripotency, epigenetic 
modifications are intrinsically required for the process 
to take place, and they have to occur all throughout the 
genome, not being just restricted to the activation or 
repression of individual genes, something that is 
already achieved by the transcription factors. This 
explains why the efficiency of reprogramming is 
significantly superior in the presence of chemicals that 
can globally interfere with epigenetic marks. For 
example, the DNA methyltransferase inhibitor 5-aza-
cytidine (AZA) causes a rapid and stable transition to a 
fully reprogrammed iPS state (Huangfu et al., 2008; 
Mikkelsen et al., 2008). Similarly, treatment with 
valproic acid (VPA), a histone deacetylase (HDAC) 
inhibitor, considerably improves the induction to 
pluripotency (Huangfu et al., 2008). Other example is 
provided by the use of the compound BIX-01294, an 
inhibitor of G9a methyltransferase that makes it 
possible to achieve reprogramming to pluripotency 
using only Oct4 and Klf4 transcription factors, with an 
efficiency comparable to the one obtained when using 
the four factors (Shi et al., 2008). In normal 
development, the biological role of G9a is to terminate 
the pluripotencial state as the progenitors exit to the 
differentiation process (Feldman et al., 2006; Epsztejn-
Litman et al., 2008). This is achieved by its histone 
methylation activity, that prevents the reactivation of its 
target genes (for example embryonic genes like Oct4) 
when their transcriptional repressors are no longer 
present (Feldman et al., 2006). Also, at the same time, 
G9a promotes DNA methylation, that stops reversion 
towards the undifferentiated state (Feldman et al., 
2006; Epsztejn-Litman et al., 2008). Therefore, 
genome-wide epigenetic changes affecting many still 
unknown loci, are essential in the late stages of  
direct reprogramming, and inhibition of the proteins 
responsible for generating or maintaining these marks 
lowers the "activation energy" required for the 
transition to pluripotency. Therefore, it makes sense 
that several of the chemical inhibitors that we have just 
mentioned are in fact already in use, or in clinical trials 
to be used as therapeutic agents against cancer. AZA 
was approved by the FDA in 2004 for the treatment of 
myelodysplastic syndromes, being the first drug into 
the new class of demethylating agents (Kaminskas et 
al., 2005). Its mechanism of action is very unspecific, 
aimed at the restoration of the normal levels of 
expression of genes whose expression has been lost due 
to promoter hypermethylation during tumoral 
progression, and that might be necessary for the control 
of proliferation and differentiation. Like in the case of 
most antitumoral drugs, AZA is expected to affect 
primarily the tumoral cells and leave non-proliferative 
cells unaffected (Sacchi et al., 1999; Kaminskas et al., 
2005). Something similar happens for HDAC inhibitors 
(Dey, 2006; Lane and Chabner, 2009). All these 
findings underscore once more the concept of cancer as 
a reprogramming disease and a case of wrong 
differentiation. 
Instructive and permissive factors in the progression 
and selection of the processes of tumoral 
reprogramming and induction of pluripotency 
We have seen how both genome-wide changes in 
epigenetic marks and the loss and/or gain of 
transcriptional regulators are essential components of 
the processes of tumour generation and reprogramming 
to pluripotency. However, it is clear that these changes 
are clearly unwanted from the points of view of normal 
development and cellular function. Therefore, cells 
have developed many built-in protection mechanisms 
to maintain their identity against these transcriptional, 
genetic and epigenetic changes. Nevertheless, all these 
mechanisms are bypassed, in one way or another 
(Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011), and cancer appears. How this 
happens in "progression to pluripotency" (in analogy to 
tumoral progression) is still to be discovered. However, 
it has recently been shown by several groups (Zhao et 
al., 2008; Banito et al., 2009; Hong et al., 2009; 
Kawamura et al., 2009; Krizhanovsky and Lowe, 2009; 
Li et al., 2009; Marión et al., 2009; Utikal et al., 2009) 
that, exactly as it happens in cancer progression, the 
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elimination of the DNA damage control checkpoint 
(p53-p21) greatly improves the efficiency of the 
reprogramming process, making it possible that many 
of the starting cells become successfully 
reprogrammed. This is done at the expense of an 
increased level of genetic instability, and most of the 
iPSCs obtained in the absence of a functional p53-p21 
axis carry genetic aberrations of different kinds. This is 
in connection with what we have mentioned before 
about reprogramming being an "uphill", unfavourable 
process, which most of the cells fail to complete 
(Mikkelsen et al., 2008). Therefore, eliminating the 
DNA damage checkpoint diminishes the selection and 
allows a larger number of cells to survive until 
pluripotency. These results support the idea of cancer 
as a disease of cellular differentiation and, furthermore, 
reinforce the idea that suggests that the driving forces 
behind the tumoral process are aberrantly expressed 
transcription factors, epigenetic regulators and 
signalling molecules, while the role of many of the 
other alterations found in tumours (for example, the 
loss of p53) is mainly permissive. 
Role of the cell of origin in tumoral reprogramming 
and induction of pluripotency 
In the study of oncogenesis, it has traditionally been 
assumed that the phenotype of the tumour cells was a 
reflection of that of the normal cell that gave rise to the 
tumour in the first place. There were some classical 
examples in which this what not the case like, for 
example, chronic myelogenous leukaemia (CML), 
where the t(9;22) chromosomal translocation could be 
found in most types of differentiated haematopoietic 
cells, therefore indicating that a common, earlier 
progenitor, should be the cell of origin (Melo and 
Barnes, 2007). But, in general, since most cancerous 
cells are reminiscent of some differentiated cell type, 
for every type of tumour, the cell of origin was 
postulated to be the corresponding normal 
differentiated cell. However, the cancer stem cell 
(CSC) theory has led to a change in our perspective 
(Cobaleda and Sánchez-García, 2009; Vicente-Dueñas 
et al., 2009a; Vicente-Dueñas et al., 2009b). The CSC 
theory proposes that tumours are stem cell-based 
tissues just like any other, and this has several radical 
consequences for our understanding of cancer. The 
most important one is the fact that not all the tumoral 
cells are equally capable of regenerating the tumour. 
This means that, when tumoral cells are experimentally 
transplanted into a new host, or when some tumour 
cells remain in the patient after incomplete tumour 
excision, the reappearance of the tumour is caused by 
just a certain tumoral cellular subpopulation. Only 
those cells, possessing stem cell characteristics, can 
give rise to the whole tumour with all its cellular 
heterogeneity. Although there can be a big range of 
variability in the percentage of CSCs within a tumour, 
from very few to 25% (Quintana et al., 2008; Cobaleda 
and Sánchez-García, 2009; Vicente-Dueñas et al., 
2009a; Vicente-Dueñas et al., 2009b), the fact is that, 
like in any other stem-cell based tissue, the majority of 
cells composing the tumour mass lack this capacity. 
Hence, if tumours are maintained by aberrant cells 
possessing stem cell characteristics, then what is the 
origin of these cells? This cancer cell-of-origin (not to 
be confused with the CSC, which would be the cancer-
maintaining cell of the already developed tumour) is 
initially a normal cell (not necessarily a stem cell) that 
will be reprogrammed by the oncogenic events in order 
to finally originate (or convert into) a tumoral cell with 
stem properties. There are two main mechanisms that 
could be invoked in this scenario. One option is that the 
cell-of-origin suffering the oncogenic mutation(s) is 
already a stem cell, which therefore becomes 
reprogrammed to give rise to a new pathological tissue 
instead of the normal one. In the case of CML, it has 
recently been demonstrated, using genetically modified 
mice, that the restricted expression of the oncogenic 
alteration in the stem cell/progenitor compartment is 
enough to generate a human-like tumour with all the 
variety of differentiated tumour cells (Pérez-Caro et al., 
2009; Vicente-Dueñas et al., 2009b). In mouse models 
of intestinal cancer it has also been found that tumours 
originate in the crypt stem cell, since when the 
oncogenic stimulus (activation of the Wnt signalling 
pathway) is targeted to the stem cell compartment, 
intestinal adenomas develop in which a developmental 
hierarchy is maintained. On the contrary, when the 
oncogenic lesions are targeted at the non-stem 
intestinal epithelial cells, they only generate short-
lived, small microadenomas (Barker et al., 2008; Zhu et 
al., 2008). In the nervous system, targeting 
astrocytoma-associated oncogenic lesions to 
progenitors (in this case in the subventricular zone) 
results in tumour development, while targeting them to 
the differentiated cells of the adult parenchyma does 
not result in tumours, only in local astrogliosis 
(Alcantara Llaguno et al., 2009). Therefore, there are 
many examples (Dirks, 2008; Joseph et al., 2008; 
Zheng et al., 2008) where it has been proven that the 
initiating event takes place in a normal stem cell, even 
if the mature tumour is composed by differentiated 
cells, indicating a true tumoral reprogramming 
mediated by the oncogenic lesions (Vicente-Dueñas et 
al., 2009b). 
The other alternative is that the cancer cell-of-origin 
can be a differentiated cell that regains stem cell 
characteristics in the process of tumoral 
reprogramming. This option relies on two 
requirements: first, the oncogenic alteration must be 
capable of conferring or programming these 
characteristics in the target cell and, second, the cell 
must be plastic enough so as to be reprogrammed by 
this precise oncogenic alteration. It has been shown that 
some oncogenes, like MOZ-TIF2 (Huntly et al., 2004), 
MLL-AF9 (Krivtsov et al., 2006; Somervaille and 
Cleary, 2006), MLL-ENL (Cozzio et al., 2003), MLL-
GAS (So et al., 2003) or PML-RARα (Guibal et al., 
2009; Wojiski et al., 2009) can generate CSCs when 
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they are introduced into committed target cells. Gene 
expression arrays have revealed that MLL-AF9 can 
activate a stem cell-like program in committed 
granulocyte-macrophage progenitors, therefore 
conferring them the property of self-renewal (Krivtsov 
et al., 2006). Also c-Myc can induce a transcriptional 
program reminiscent of that of embryonic stem cells in 
differentiated epithelial cells, and originate epithelial 
CSCs (Wong et al., 2008). However, other oncogenes 
are unable of conferring self-renewal properties, like 
for example BCR-ABLp190 (Huntly et al., 2004). In 
these cases the oncogene, since it cannot immediately 
confer stem cell properties, could give rise to a 
precancerous cell that can afterwards, with the presence 
of additional alterations conferring "stemness", give 
rise to the cancer stem cell (Chen et al., 2007). In any 
case, the cellular origin where the cancer-initiating 
lesions take place is difficult to determine since, in 
many cases, the functional impact of the oncogenic 
lesion (i.e. the tumour clonal expansion) can present 
with phenotypes mimicking differentiation stages that 
can be either upstream or downstream of the initiating 
cell. For example, the translocations that are the 
initiating lesions of many childhood B acute 
lymphoblastic leukaemias (ALL) originate in utero 
during embryonic haematopoiesis and promote the 
conversion of partially committed cells into 
preleukaemic cells with altered self-renewal and 
survival properties, that will require a second postnatal 
hit to develop into full leukemias (Hong et al., 2008). 
Also, in leukemias carrying the AML1-ETO 
translocation, this aberration can be detected in stem 
cells in patients in remission. These stem cells behave 
apparently normal during the remission phase, 
indicating that they can remain dormant and, with time, 
some of their descendants can become tumorigenic and 
originate the relapse (Miyamoto et al., 2000). We have 
described previously that, in mice, the loss of Pax5 in 
mature B cells leads to the dedifferentiation to 
multipotent progenitors and the appearance of 
progenitor B cell lymphomas (Cobaleda et al., 2007a). 
In human Hodking lymphomas, the overexpression of 
specific antagonists leads to the functional inactivation 
of the B cell factor E2A, which in turn causes the loss 
of B cell markers and induces the expression of 
lineage-inappropriate genes characteristic of the Reed-
Sternberg Hodking lymphoma cells (Mathas et al., 
2006). Also in children's B-ALLs, the CSCs can 
present with the phenotypes of different stages of early 
B cell development that, on top of that, can apparently 
interconvert among them, therefore complicating even 
more the task of identifying the cancer-cell of origin (le 
Viseur et al., 2008). A genomic analysis of samples 
from relapsed ALL patients, when compared with the 
samples at diagnosis, has shown that the same ancestral 
clone can be found at both stages of the disease 
(Mullighan et al., 2008). So, clearly in many cases the 
cancer-maintaining cell evolves over time and adapts to 
treatment to finally lead to relapse, and therefore the 
characteristics of the CSC population in a certain 
moment may not relate at all any more to those of the 
initial cancer cell-of-origin (Barabé et al., 2007). 
As we already mentioned when we described the view 
of reprogramming to pluripotency from the perspective 
of the GRNs, the inducing factors are not required 
anymore once the cells have reached the pluripotent 
condition and the new identity (however plastic this is) 
has been established. If cancer stem cells are generated 
by a tumoral reprogramming process, then maybe the 
oncogenes that initiate tumour formation might be not 
be required for tumour progression (Krizhanovsky and 
Lowe, 2009). If this were the case, it would explain the 
aforementioned examples in which a pre-cancerous 
lesion exists stably in an aberrant cell population that 
does only evolve to an open tumour when secondary 
mutations occur. In this scenario, the initiating lesion 
would be the driving force in the reprogramming 
process, but once this has been completed, it would 
only be a passenger mutation, or could even perform a 
different role that would be independent from its 
reprogramming capacity, like for example in tumour 
expansion/proliferation. A mechanism of this kind 
would explain why some targeted therapies fail in spite 
of their initial apparent efficacy: for example, imatinib, 
a drug targeted against the deregulated kinase activity 
of BCR-ABL, successfully eliminates differentiated 
tumour cells, but it fails to kill the BCR-ABL+ CSCs, 
since it does not seem to interfere with the function of 
the chimeric oncogene in this cellular context (Graham 
et al., 2002; Barnes and Melo, 2006). 
The fact that CSCs can originate from differentiated 
cells represents the last and most patent similarity 
between tumorigenesis and reprogramming to 
pluripotency. Also in iPSCs generation, the nature of 
the cell of origin is key in determining the global 
success. In this way, it has been described that, in the 
haematopoietic system, the capacity of reprogramming 
cells decreases as they differentiate, since HSC are 300 
times more likely to be reprogrammed than B or T cells 
(Eminli et al., 2009). In the case of the nervous system, 
when the starting cells are adult neural stem cells 
(NSCs), then pluripotency can be achieved using only 
Oct4 (Kim et al., 2009), probably because of the high 
similarity of NSCs transcriptional profile to that of ES 
cells. Similarly, in a liver model of transdetermination 
it has been demonstrated that Neurogenin3 can convert 
hepatic progenitor cells into neo-islets but it cannot 
transdifferentiate mature hepatocytes (Yechoor et al., 
2009). 
Outlook 
The knowledge obtained in the research of the 
molecular and cellular mechanisms that control cellular 
plasticity, pluripotency and reprogramming will also 
have a profound impact in our understanding of 
tumorigenesis and, in a more distant future, in the 
treatment of cancer. It is clear that the two fields of 
research will continue being mutually interdependent. 
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By way of example, the main obstacle for the future 
use of iPSCs in the clinic is precisely the generation of 
tumours as a result of uncontrolled growth or 
differentiation of the cells, once they are in the patient. 
Therefore, the knowledge and control of the narrow 
limits of gene expression that mark the difference 
between normal and tumoral differentiation and 
reprogramming will be required before this problem 
can be overcome. 
Assuming the role that reprogramming plays in cancer 
generation makes it possible to initiate the development 
of new therapeutic strategies aimed at re-directing the 
wrong differentiation program towards a new outcome 
(ideally, in most cases, terminal non-tumoral 
differentiation and cellular death). Differentiation 
therapies are already in use in some cases, like the 
administration of retinoic acid to differentiate tumoral 
cells in PML-RARα+ positive acute promyelocytic 
leukemias. We have described how reprogramming to 
pluripotency, due to its inefficiency, can get caught up 
at several points before reaching the iPSC state 
(Mikkelsen et al., 2008). Tumoral cells are probably 
very close to these incompletely reprogrammed 
intermediates, and the study of the latter should help us 
in understanding how to get the former ones out of their 
pathologic block. In fact, epigenetic therapies are most 
probably going to be on the rise in the coming years for 
the treatment of many types of tumours, since our 
knowledge about the molecular mechanisms 
controlling the epigenetic marks and their role in self-
renewal, differentiation and maintenance is increasing 
very quickly, and this should help us to obtain more 
and better (more specific) epigenetic drugs (Jones, 
2007; Shen et al., 2009). 
The discovery of reprogramming to pluripotency has 
transfigured the research in the field of cellular 
plasticity. It is nowadays possible, using just three 
ectopic factors, to reprogram fibroblasts into functional 
neurons (Vierbuchen et al., 2010), to convert in vivo 
pancreatic exocrine cells to β cells (Zhou et al., 2008) 
or to directly transdifferentiate mouse mesoderm into 
heart tissue (Takeuchi and Bruneau, 2009). One of the 
most remarkable examples in this context is the 
phenotype caused by the deletion of a single gene, 
Foxl2, in adult ovarian follicles. This inactivation 
immediately upregulates testis-specific genes and leads 
to a full organ reprogramming (Uhlenhaut et al., 2009) 
that shows that the maintenance of the identity of the 
ovarian cells requires the active and constant presence 
of a specific gene. This is therefore an active process 
that resembles very much what we have described for 
Pax5 and B cells, but affecting a whole organ with all 
its cellular diversity. 
Our increasing knowledge and technical control over 
cellular identity should help us in the development of 
strategies for the reprogramming of tumoral cells. In 
fact, several experimental evidences seem to suggest 
that this is perfectly possible. For example, melanoma  
cells can be reprogrammed by nuclear transplantation 
(Hochedlinger et al., 2004). Also, embryonal carcinoma 
cells or mouse brain tumours have been used as a valid 
starting material for nuclear cloning experiments (Li et 
al., 2003; Blelloch et al., 2004). Therefore, maybe in a 
not so distant future we might have the knowledge and 
tools to manipulate tumoral cell identity to force cancer 
cells to differentiate, or to make them vulnerable to 
therapy. 
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